Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 3Gastrointestinal 3Plasma cell 2Gynecologic 2Tumor-Agnostic 1Thoracic 1Sarcoma 1Myeloid 1Lymphoid 1Head & Neck 1Genitourinary 1CNS 1Breast 1

Conditions

Nasopharyngeal Carcinoma 1

Interventions

Cisplatin 630Radiotherapy 339pembrolizumab 329Cetuximab 283Docetaxel 225Radiotherapy, Intensity-Modulated 221Fluorouracil 199Carboplatin 198Paclitaxel 161Nivolumab 145Gemcitabine 125Magnetic Resonance Spectroscopy 99Radiation 91Drug Therapy 86Capecitabine 76toripalimab 74Surveys and Questionnaires 73Surgical Procedures, Operative 72Biopsy 62durvalumab 61Chemoradiotherapy 52Blood Specimen Collection 52Cyclophosphamide 48Specimen Handling 47camrelizumab 46Radiosurgery 46Erlotinib Hydrochloride 46Standard of Care 43130-nm albumin-bound paclitaxel 43tislelizumab 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cell Count × Head & Neck × Clear all
NCT03648697 2020-08-11

EBV-TCR-T(YT-E001)for Patients With EBV-positive Recurrent or Metastatic NPC

Fujian Cancer Hospital

Phase 2 Unknown
20 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡